Literature DB >> 12659381

Vaccine interchangeability.

David P Greenberg1, Sandor Feldman.   

Abstract

The recommended childhood immunization schedule is complex, with multiple doses of vaccines required to complete the series. For a variety of reasons, a single manufacturer's product may not be available for all of the doses needed. In addition, combination products may become available, allowing for fewer injections to be administered but resulting in a change of vaccine components. To ensure the timely immunization of children and to avoid missed opportunities to vaccinate, it is important to be familiar with data documenting the interchangeability of vaccines. Although clear evidence is available to demonstrate the interchangeability of some vaccines (i.e., hepatitis B vaccines and Haemophilus influenzae type b vaccines), it is more difficult to evaluate the interchangeability of others (i.e., diphtheria-tetanus-acellular pertussis [DTaP] vaccines). Limited data support the interchangeability of some DTaP products when necessary. This article presents the safety and immunogenicity data for immunization regimens that use vaccines from different manufacturers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12659381     DOI: 10.1177/000992280304200201

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  4 in total

1.  Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts.

Authors:  A Orsi; C Azzari; E Bozzola; G Chiamenti; G Chirico; S Esposito; F Francia; P Lopalco; R Prato; R Russo; A Villani; E Franco
Journal:  J Prev Med Hyg       Date:  2018-06-01

Review 2.  Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology.

Authors:  E Chiappini; C Petrolini; C Caffarelli; M Calvani; F Cardinale; M Duse; A Licari; S Manti; A Martelli; D Minasi; M Miraglia Del Giudice; G B Pajno; C Pietrasanta; L Pugni; M A Tosca; F Mosca; G L Marseglia
Journal:  Ital J Pediatr       Date:  2019-11-19       Impact factor: 2.638

3.  Cross-Reactivity between Half Doses of Pfizer and AstraZeneca Vaccines-A Preliminary Study.

Authors:  Krzysztof Lukaszuk; Amira Podolak; Paulina Malinowska; Jakub Lukaszuk; Grzegorz Jakiel
Journal:  Vaccines (Basel)       Date:  2022-03-27

4.  Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial.

Authors:  Suman Kanungo; Pranab Chatterjee; Ashish Bavdekar; Manoj Murhekar; Sudhir Babji; Richa Garg; Sandip Samanta; Ranjan K Nandy; Anand Kawade; Kangusamy Boopathi; Kaliaperumal Kanagasabai; Vineet Kumar Kamal; Velusamy Saravana Kumar; Nivedita Gupta; Shanta Dutta
Journal:  Lancet Infect Dis       Date:  2022-05-16       Impact factor: 71.421

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.